Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Belzutifan / MK-6482 for the Treatment of Advanced Pheochromocytoma / Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), or Von Hippel-Lindau (VHL) Disease-Associated Tumors (MK-6482-015)
Multiple Cancer Types
This is a study to evaluate the efficacy and safety of Belzutifan monotherapy in participants with advanced pheochromocytoma / paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET) or von Hippel-Lindau (VHL) Disease-Associated Tumors. The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).